| Market Cap | ₹97,563 CrPharmaceuticals |
|---|---|
| Revenue TTM | ₹34,935 CrOperating Revenue |
| RSI | 57.04Neutral Zone |
| PE TTM | 24.76Industry PE 49.08 |
Key highlights
- Received final USFDA approval for Beclomethasone Dipropionate HFA Inhalation Aerosol (40 mcg and 80 mcg)
- Marks Aurobindo’s first ever metered-dose inhaler (MDI) product approval
- Addressable US market for the reference product estimated at US$301 million by IQVIA
- Production to be localized at the Raleigh facility in North Carolina via subsidiary Aurolife Pharma LLC
- Total cumulative USFDA ANDA approvals reached 596, including 571 final approvals
What Approval Was Received?
Aurobindo Pharma Limited has secured final approval from the US Food & Drug Administration (USFDA) to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths. This product serves as a generic equivalent to Teva’s QVAR Inhalation Aerosol. The approval represents a technical milestone as it is the company's first metered-dose inhaler (MDI) product.
The therapeutic is indicated for the maintenance treatment of asthma as a prophylactic therapy in patients aged five years and older, potentially reducing or eliminating the need for systemic corticosteroids in chronic asthma management.
Strategic Significance of MDI Entry
- Facilitates expansion into complex respiratory therapies and high-barrier inhalation segments.
- Strengthens the US portfolio which now includes 571 final USFDA approvals.
- Targets an addressable market estimated at US$301 million for the 12 months ended July 2026.
- Leverages specialized manufacturing capabilities at the North Carolina facility.
- Establishes a footprint in differentiated generics to drive next-wave US market growth.
Path to Market and Commercialisation
The newly approved inhalation aerosol will be manufactured at Aurobindo Pharma’s Raleigh facility in North Carolina. This site is owned and operated by its wholly owned step-down subsidiary, Aurolife Pharma LLC. The company has indicated that the commercial launch of the product is expected to commence in the upcoming quarters.
This move underscores Aurobindo's strategy to localize manufacturing for complex products within the US market, ensuring supply chain resilience while targeting high-value respiratory care segments that require sophisticated delivery mechanisms like metered-dose inhalers.
Financial and Market Context
- TTM Net Profit stands at ₹3,940.28 crore with a quarterly growth of 25.2% year-on-year.
- Company maintains a high Durability Score of 75/100.
- The stock is trading at a TTM P/E of 24.76x, significantly lower than the sector average of 49.41x.
- Promoter holding remains stable at 51.88% as of the latest filing.
- Institutional investors, including FIIs and Mutual Funds, hold a combined 41.48% stake.
| Share price | ₹1679.8 |
|---|---|
| Market capitalisation | ₹97,563.05 Cr |
| Revenue (annual) | ₹33,653.08 Cr |
| Net profit (annual) | ₹3,504.75 Cr |
| Revenue (latest quarter) | ₹9,150.35 Cr+3.35% vs previous quarter |
| Net profit (latest quarter) | ₹1,032.56 Cr+12.08% vs previous quarter |
| P/E (TTM) | 24.76×Sector 49.41× |
| Promoter holding | 51.88%+0.06% QoQ |
| FII holding | 16.38%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Aurobindo Pharma Limited announcing the receipt of USFDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol. Market figures from a third-party data provider.
